You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華邦健康(002004.SZ):全資子公司藥品阿那曲唑片通過一致性評價
格隆匯 03-20 11:45

格隆匯3月20日丨華邦健康(002004.SZ)公佈,公司全資子公司華邦製藥於近日收到國家藥品監督管理局核准簽發的關於阿那曲唑片(瑞婷)的《藥品補充申請批件》,該藥品通過國家仿製藥質量和療效一致性評價。

阿那曲唑片原研廠家為ANI Pharmaceutical製藥公司,該產品於1995年在美國獲批上市。阿那曲唑片適用於絕經後婦女的晚期乳腺癌的治療、絕經後婦女激素受體陽性的早期乳腺癌的輔助治療、曾接受2到3年他莫昔芬輔助治療的絕經後婦女激素受體陽性的早期乳腺癌的輔助治療。

阿那曲唑片已被應用於臨牀多年,為《國家基本醫療保險、工傷保險和生育保險藥品目錄(2020年版)》乙類品種。

公司表示,此次公司全資子公司華邦製藥的藥品阿那曲唑片通過一致性評價,將提高公司產品的市場競爭力,同時為公司後續產品開展仿製藥一致性評價工作積累了寶貴的經驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account